Authors
Omji Porwal, Rozhan Arif Muhammed, Sharad Visht, Sama Naziyah Shaban, Zainab Yalman Othman, Alaa Amer, Amit Singh, Bimlesh Kumar Singh
Published in
Clinica chimica acta; international journal of clinical chemistry. Pages 122982. Nov 17, 2026. Epub Nov 17, 2026.
Abstract
In non-small cell lung cancer (NSCLC), plasma circulating tumor deoxyribonucleic acid (ctDNA) testing allows the detection of actionable mutations, such as epidermal growth factor receptor (EGFR) mutations, including exon 19 deletions, L858R, T790M, and C797S. However, liquid-biopsy workflows primarily rely on centralized platforms, such as droplet digital polymerase chain reaction (ddPCR), quantitative polymerase chain reaction (qPCR), amplification-refractory mutation system polymerase chain reaction (ARMS-PCR), and next-generation sequencing (NGS), which may not enable rapid or decentralized testing. We reviewed the existing data on the use of Cas12a for plasma ctDNA detection and emerging Cas12a/Cas13a strategies for detecting exosomal microRNAs (miRNAs) and circular RNAs (circRNAs), distinguishing established plasma ctDNA testing from early CRISPR-Cas and exosomal RNA studies. Laboratory factors that impact implementation, such as specimen selection, preanalytical variability, matrix effects, reproducibility, quality control, clinically relevant decision thresholds, turnaround time, and cross-platform validation with established ddPCR and NGS workflows, are also highlighted. CRISPR-Cas biosensors demonstrate potential as a fast and specific method for EGFR genotyping during diagnosis and targeted testing upon progression in addition to validated molecular assays. Postoperative minimal residual disease surveillance remains investigational. Standard workflows, external test performance validation, clinically relevant cutoffs, and integration of the test into reflex molecular diagnostic workflows are necessary for clinical translation.
PMID:
43044907
Bibliographic data and abstract were imported from PubMed on 18 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 8
- Comments 0